Find patient medical information for aripiprazole oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings
the mania symptoms of bipolar disorder, where your mood changes from feeling highly FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the
Lundbeck A/S (Lundbeck) announce the U
RSS
ABILIFY (aripiprazole) Oral Tablets, Orally-Disintegrating Tablets, and Oral Solution are indicated for the treatment of: • Schizophrenia • Acute Treatment of Manic and Mixed
The U
Please contact Otsuka America Pharmaceutical, Inc
Learn how to help patients get treatment with ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension through the Integrated Pharmacy Network
Retail pharmacy option: With this Savings Card, eligible, commercially insured patients can save on their out-of-pocket costs and pay as little as $5 per co-pay for each of their ABILIFY prescriptions
Your healthcare provider may give you your ABILIFY ASIMTUFII injection, or you can receive it at a Local Care Center (LCC), giving you more options to choose the treatment location that works best for you
Food and Drug Administration (FDA) acceptance of their New Drug Application (NDA) for aripiprazole 2-month, ready-to-use, long-acting injectable, a medication administered for
, Ltd
Common side effects of aripiprazole may include: feeling restless; pain where the medicine was injected; weight gain; or
Aripiprazole side effects (more detail) Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) by Otsuka Pharmaceuticals (UK) Ltd Learn about resources for ABILIFY MAINTENA® (aripiprazole)
antipsychotics including ABILIFY
Read FULL PRESCRIBING INFORMATION, including BOXED WARNING and MEDICATION GUIDE
Development History
In contrast, aripiprazole injection (9
Otsuka Pharmaceutical Co
is a Phase 3 clinical study of the IM depot formulation of aripiprazole that was designed to evaluate the efficacy, safety and tolerability of the intramuscular formulation as a maintenance treatment in patients with schizophrenia